MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
STERIS plc Operating Income 2011-2026 | STE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income STERIS plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 867 M | 836 M | 791 M | 478 M | 548 M | 537 M | 411 M | 400 M | 226 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 867 M | 226 M | 566 M |
Quarterly Operating Income STERIS plc
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 273 M | 266 M | 246 M | - | 245 M | 220 M | 186 M | - | 226 M | 192 M | 198 M | - | 191 M | -306 M | 158 M | - | 203 M | 334 M | 131 M | - | 147 M | 147 M | 141 M | 114 M | 142 M | 142 M | 127 M | 110 M | 69.6 M | 107 M | 94.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 334 M | -306 M | 158 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 184.86 | 1.31 % | $ 53.2 B | USA |
 |
Baxter International
BAX
|
-308 M | $ 21.74 | 1.85 % | $ 11.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 11.29 | -8.21 % | $ 228 M | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 155.85 | 4.08 % | $ 3.84 B | USA |
 |
Alcon
ALC
|
580 M | $ 82.21 | -1.21 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
-9.45 M | $ 32.79 | 1.27 % | $ 1.57 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 6.16 | -0.16 % | $ 34 K | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.58 | -0.56 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 92.55 | 0.75 % | $ 2.08 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 11.22 | 0.13 % | $ 458 M | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 7.9 | - | $ 163 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 84.11 | 0.51 % | $ 16.7 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 61.61 | 1.55 % | $ 3.1 B | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 150.56 | -5.24 % | $ 4.82 B | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 119.69 | 2.21 % | $ 5.8 B | USA |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 4.72 | 0.64 % | $ 215 M | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.76 | -2.47 % | $ 205 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 175.38 | 0.03 % | $ 9.35 B | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 504.2 | 0.93 % | $ 180 B | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 82.25 | 0.5 % | $ 4.79 B | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.07 | -3.95 % | $ 21.1 M |  Israel |
 |
Nephros
NEPH
|
-1.59 M | $ 4.14 | 6.43 % | $ 43 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.26 | -2.04 % | $ 20.7 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-879 M | $ 12.63 | 0.88 % | $ 2.57 B | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 29.16 | 1.53 % | $ 4.9 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 39.55 | 1.41 % | $ 130 M | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 21.98 | -12.38 % | $ 1.48 B | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | - | - | $ 31.1 M | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.08 | -0.24 % | $ 168 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 136.76 | -0.34 % | $ 7.62 M | USA |
 |
ResMed
RMD
|
1 B | $ 258.04 | 0.68 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 23.17 | -0.26 % | $ 1.07 B | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.67 | -3.48 % | $ 20.1 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 17.65 | -1.29 % | $ 867 M | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 115.88 | 3.65 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 67.96 | 2.09 % | $ 247 M | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 241.54 | -0.94 % | $ 17.5 B | USA |